Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Alto Neuroscience, Inc.NYSE: ANRO

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

Latest · FY2021
-4374.8%
Year-over-year change
—

Net Margin vs competitors

How ANRO compares with its peers on the latest reported figures

ANRO Competitors Peer median
Net Margin for ANRO and competitors
Company Period LTM level YoY 3-year change
AMRNAmarin Corporation plcLTM Mar 2026-15.6% +25.4 pp+10.5 pp
CLLSCellectis S.A.LTM Mar 2026-98.8% +28.3 pp+461.0 pp
ACIUAC Immune S.A.LTM Mar 2026-1788.8% -1604.7 pp-173.6 pp
KRROKorro Bio, Inc.LTM Mar 2026-2954.1% -1141.0 pp—
SLNSilence Therapeutics plcLTM Mar 2026-9243.0% —-15619.4 pp
ANROAlto Neuroscience, Inc.FY2025— ——
DRTSAlpha Tau Medical Ltd.FY2025— ——
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
LRMRLarimar Therapeutics, Inc.FY2025— ——
DBVTDBV Technologies S.A.FY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding ANRO) -1788.8%-557.8 pp-81.6 pp

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue210K0000
Cost of Revenue145K342K0502K661K
Gross Profit65K(342K)0(502K)(661K)
Gross Margin31.0%————
Research & Development8.37M23.69M30.29M47M45.62M
Selling, General & Admin3.75M5.16M7.52M21.61M20.75M
Operating Expenses12.12M28.85M37.81M68.11M65.7M
Depreciation & Amortization145K342K373K502K661K
EBITDA(9.04M)(27.37M)(34.56M)(62.3M)(60.11M)
EBITDA Margin-4305.7%————
Operating Income(12.06M)(29.19M)(37.81M)(68.61M)(66.36M)
Operating Margin-5741.0%————
Interest Income2K114K2.35M8.85M6.6M
Interest Expense001.37M(1.38M)2.47M
Other Income / Expenses2.87M1.48M1.5M7.18M3.13M
Income Before Tax(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Pre-Tax Margin-4374.8%————
Income Tax Expense00000
Net Income(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Net Margin-4374.8%————
EPS (Basic)(0.36)(1.08)(1.35)(2.50)(2.19)
EPS (Diluted)(0.36)(1.08)(1.35)(2.50)(2.19)
Weighted Avg Shares25.57M25.57M26.88M24.6M28.85M
Weighted Avg Shares (Diluted)25.57M25.57M26.88M24.6M28.85M

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.